LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 137.43% | 76.16% | 74.28% | 71.62% | -1.74% |
| Total Depreciation and Amortization | 31.32% | 7.16% | 16.02% | 14.01% | 4.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -130.28% | 1.26% | 2.10% | 1.85% | 771.70% |
| Change in Net Operating Assets | 47.41% | -10.32% | -193.40% | -342.42% | -338.63% |
| Cash from Operations | 76.43% | 77.88% | 42.05% | 44.17% | -122.38% |
| Capital Expenditure | -145.32% | -3,354.13% | -2,009.66% | -106.43% | 39.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -584.73% | -161.38% | -135.58% | -240.75% | -2,233.59% |
| Cash from Investing | -613.75% | -1,344.40% | -1,114.13% | -135.32% | 3.86% |
| Total Debt Issued | 95.36% | -40.26% | 22.36% | 46.27% | 25.25% |
| Total Debt Repaid | -41.88% | -12.36% | 20.09% | 46.93% | -148.28% |
| Issuance of Common Stock | -13.03% | -13.03% | -31.80% | -82.62% | 248.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.98% | 77.87% | 63.88% | 76.13% | -64.53% |
| Cash from Financing | 14.40% | -18.04% | 4.45% | -41.05% | 133.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18,772.73% | 261.00% | -173.64% | -402.19% | 100.19% |